UFP Technologies shares surge 11.41% after-hours after reporting strong Q3 results, beating revenue and EPS estimates with positive guidance.

UFP Technologies surged 11.41% in after-hours trading following the announcement of strong Q3 2025 results. The company reported $154.6 million in sales, a 6.5% year-on-year increase, and adjusted EPS of $2.39, exceeding analyst estimates by 10%. Despite a $3 million labor cost impact at its Illinois facility, CEO R. Jeffrey Bailly highlighted progress in resolving operational issues and noted that EPS would have grown 13% without the expense. The company also outlined strategic advancements, including new robotic surgery programs set to launch by year-end and successful integration of recent acquisitions. Positive guidance for future revenue growth, driven by expanded contracts and facility expansions in the Dominican Republic, further buoyed investor sentiment. The results underscored UFP’s resilience and long-term growth potential in the medical device manufacturing sector.